Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Fludarabine Workflow for DNA Synthesis Studies
2026-08-13
Build a reproducible Fludarabine workflow that connects DNA replication stress with cell-cycle arrest and apoptosis readouts. Practical dosing, solubility control, genotype-aware design, and troubleshooting make it useful for leukemia research, multiple myeloma research, and translational assay development.
-
MSNs@SF-HA-FA Targets NSCLC Metastasis
2026-08-12
Li et al. identify an SPI1/miR-616-5p regulatory axis that promotes non-small cell lung cancer invasion and migration, and show that sulforaphane can inhibit this pathway. A hyaluronic acid- and folic acid-modified mesoporous silica nanoparticle system improves sulforaphane stability, uptake, tumor targeting, and anti-metastatic activity in NSCLC xenograft models.
-
Gramine: From Target Engagement to Ferroptosis
2026-08-12
Gramine is a mechanism-rich ferroptosis inducer for cancer biology research, with particular relevance to triple-negative breast cancer. This article explains how to distinguish CUL3–MTDH target engagement from downstream cell-death phenotypes and design more defensible assays.
-
Chemotherapy Enhances Neoantigen-Directed T Cell Therapy
2026-08-11
Sagie et al. identify the KRAS.G12V-specific TCR T104 and show that lymphodepleting chemotherapy improves neoantigen-directed killing by increasing immunoproteasome activity, HLA-I expression, and peptide presentation. The study provides a mechanistic framework for optimizing chemotherapy before TCR-T cells, tumor-infiltrating lymphocytes, or T cell engagers, while emphasizing that the evidence remains preclinical.
-
Firefly Luciferase mRNA: Workflow & Optimization
2026-08-11
Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) provides a sensitive, non-destructive readout for transfection benchmarking, gene expression assays, cell viability assays, and delivery studies. Its capped, modified architecture helps researchers distinguish payload performance from formulation or handling failures.
-
Intravesical p21 mRNA–LNP Therapy in Bladder Cancer
2026-08-10
The reference study develops chemically modified p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. Its experiments connect bladder-restricted protein expression with tumor suppression in an orthotopic mouse model, while also defining important mechanistic and translational limitations for mRNA-based tumor suppressor replacement.
-
Dextrose in Hypoxic Tumor Models
2026-08-09
Dextrose (D-glucose) is more than a routine carbon source in glucose metabolism research. This article shows how to use it as a defined experimental variable for modeling nutrient competition, hypoxia, and immune dysfunction in tumor microenvironments.
-
Capecitabine in Tumor–Stroma Precision Testing
2026-08-08
Capecitabine is more than a 5-fluorouracil prodrug: it is a mechanistically informative probe for studying activation biology, tumor–stroma interactions, and response heterogeneity. By combining its thymidine phosphorylase-linked activation with patient-derived gastric cancer assembloids, translational researchers can build more discriminating preclinical oncology research workflows while avoiding overinterpretation of tumor-only assays.
-
Benzyl-activated Streptavidin Magnetic Beads: Assay Design
2026-08-07
Discover how Benzyl-activated Streptavidin Magnetic Beads support selective biotinylated molecule capture, from immunoprecipitation to mechanistically informed cell-death workflows. This guide connects annexin-V biology with practical magnetic separation while clearly distinguishing validated evidence from experimental adaptation.
-
Technical Guide: EdU Flow Cytometry Assay Kits (Cy5) for S-P
2026-08-07
The EdU Flow Cytometry Assay Kits (Cy5) enable robust detection of S-phase DNA synthesis in proliferating cells using copper-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry. This kit is best suited for flow cytometry–based cell proliferation assays where denaturation-free workflow, multiplexing, and high sensitivity are required. Applications beyond flow cytometry or fixed tissue analysis are not validated.
-
LY-411575: Gamma-Secretase Inhibitor for Precision Pathway R
2026-08-06
LY-411575 empowers researchers to dissect amyloid beta and Notch pathways with high selectivity, enabling advanced Alzheimer's and cancer studies. This guide translates recent breakthroughs into actionable workflows, protocol optimizations, and troubleshooting insights for maximum experimental reliability.
-
Topotecan HCl in DNA Damage Research: New Insights & Assay I
2026-08-06
Explore how Topotecan HCl, a topoisomerase 1 inhibitor, advances DNA damage research and assay design for oncology. This article uniquely bridges neuroinflammatory DNA repair insights with practical guidance for antitumor studies.
-
RIPA Lysis Buffer (Strong): Precision Tools for Neuroimmune
2026-08-05
Explore how RIPA Lysis Buffer (Strong) enables high-fidelity protein extraction from animal tissues and cells, underpinning advanced neuroimmune and exosome research. This cornerstone article provides scientific depth and unique assay insights not found elsewhere.
-
Schlafen-11 and -9 as Sensors for Intracellular ssDNA in Imm
2026-08-05
The reference study identifies Schlafen-11 (SLFN11) and its murine homolog SLFN9 as innate immune sensors that directly bind intracellular single-stranded DNA (ssDNA) containing CGT motifs, triggering cytokine expression and cell death. This work clarifies a longstanding gap in the understanding of cytoplasmic DNA sensing and innate immune activation, with potential implications for gene therapy and nucleic acid delivery research.
-
Lanabecestat (AZD3293): Applied BACE1 Inhibition in Alzheime
2026-08-04
Lanabecestat (AZD3293) offers precise, blood-brain barrier-penetrant BACE1 inhibition for translational Alzheimer’s disease research. Discover optimized workflows, troubleshooting strategies, and the practical impact of partial amyloid-beta reduction, as revealed by recent landmark studies.